Does Medicare Cover Mounjaro in 2026? A Caregiver’s Guide to Coverage, Prior Authorization, and Appeals

Short answer

Medicare Part D covers Mounjaro for type 2 diabetes with prior authorization; tier placement, step-therapy rules, and your plan design decide what you pay. It does not cover Mounjaro for weight loss alone under federal statute. Starting July 1, 2026, a separate 18-month CMS demonstration called the Medicare GLP-1 Bridge provides $50-per-month access to Wegovy, Zepbound KwikPen, and Foundayo for eligible beneficiaries with obesity plus cardiovascular or metabolic conditions — but it excludes people with type 2 diabetes.

Why the Medicare Mounjaro question has three different answers in 2026

If you have looked online for a simple answer, you have already noticed the problem: some pages say Medicare covers Mounjaro, others say it does not, and a third group talks about a brand-new $50-per-month program that seems to say something different again.

All three are partly right. Coverage depends on three variables that shift the answer: which molecule your prescription is written for (Mounjaro versus Zepbound versus Wegovy), which indication the prescriber wrote it for (type 2 diabetes versus weight loss versus a cardiovascular indication), and which pathway is paying (standard Part D versus the new Medicare GLP-1 Bridge demonstration).

This guide walks through each answer in turn — starting with the most common Medicare Mounjaro question: coverage for type 2 diabetes.

Does Medicare Part D cover Mounjaro for type 2 diabetes?

Yes. Mounjaro is FDA-approved for type 2 diabetes, and Medicare Part D plans cover it broadly. A JAMA Network Open cross-sectional analysis of CMS Basic Drugs Formulary File data found that 92.9% of Part D quarter-plan observations included injectable tirzepatide (Mounjaro’s molecule) by Q3 2024 — up from 26.5% in Q3 2022.

Coverage does not mean unconditional access. Three plan-level mechanics decide what your prescription costs and how quickly you can start:

Prior authorization. In practice this means your prescriber submits documentation showing medical necessity — usually including your diabetes diagnosis, prior treatment history, and evidence that other agents have been tried or ruled out. The same JAMA study found that Part D prior-authorization requirements on tirzepatide rose from under 25% in Q3 2023 to 83.2% by Q3 2024. If your plan sits in that 83%, expect a PA step before the first fill.

Step therapy. Most Part D plans require documented failure or intolerance of at least one lower-cost diabetes agent — typically metformin, sometimes a second oral agent — before covering tirzepatide. Your plan’s Evidence of Coverage lists the specific sequence.

Tier placement. Mounjaro usually sits on Tier 3 (preferred brand) or a specialty tier, which means a copay in the $47-to-$100-plus range each month after your deductible, depending on plan design and your progress through the coverage phases.

The average monthly out-of-pocket cost for Mounjaro under Medicare Part D nearly doubled from $99 in 2024 to $196 in 2025 according to a University of Pennsylvania Leonard Davis Institute of Health Economics analysis. Cost variability is real, and your plan’s specific tier structure will tell you more than a category-average figure.

Does Medicare cover Mounjaro for weight loss?

No — and the answer needs a small clarification, because Mounjaro is not the FDA-approved brand for weight loss in the first place. Eli Lilly sells the same molecule, tirzepatide, under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. If a Medicare beneficiary receives a prescription for Mounjaro with a weight-loss indication, Part D standard rules will not cover it.

The reason is statutory, not clinical. Under federal statute (Social Security Act §1860D-2(e)(2)), Medicare Part D is prohibited from covering weight-loss drugs. That prohibition has held for two decades and applies to Wegovy, Zepbound, and any other agent whose approved indication is weight loss alone.

There are three important exceptions layered on top:

• Cardiovascular indications. When a GLP-1 is FDA-approved for a specific cardiovascular indication in a beneficiary with obesity — for example, Wegovy’s approval for reducing major cardiovascular events in adults with established cardiovascular disease and obesity — Part D can cover the drug under the cardiovascular indication. The coverage decision hinges on how the prescription is coded and on your plan’s formulary.
• Comorbid type 2 diabetes. A beneficiary who has both obesity and type 2 diabetes can be prescribed Mounjaro under the diabetes indication and gets Part D coverage on that basis, regardless of weight-loss benefit as a secondary outcome.
• The Medicare GLP-1 Bridge. A separate demonstration program (covered in the next section) provides a temporary path to a different set of weight-loss GLP-1s for a specific eligible population — outside Part D.

For most Medicare beneficiaries whose prescriber writes “Mounjaro for weight loss,” the answer under standard Part D is no. The next section covers the demonstration that opened a partial door.

The Medicare GLP-1 Bridge program: what’s new in 2026

CMS announced the Medicare GLP-1 Bridge program on May 6, 2026. The 18-month demonstration went live July 1, 2026 and runs through December 31, 2027. It provides $50-per-month access to three FDA-approved GLP-1 formulations for eligible Medicare beneficiaries — outside the Part D benefit structure.

What the Bridge covers. Three formulations are included: Foundayo, Wegovy, and Zepbound KwikPen. Mounjaro itself is not on the Bridge list — because Mounjaro is the type 2 diabetes brand, which has its own Part D coverage path. The Bridge is designed to close the weight-management gap that Part D’s statutory exclusion leaves open.

Who qualifies. Eligibility uses BMI thresholds combined with condition criteria:

• BMI 35 or higher.
• Or BMI 30 or higher with heart failure, uncontrolled hypertension, or chronic kidney disease stage 3a or higher.
• Or BMI 27 or higher with pre-diabetes, prior heart attack, prior stroke, or peripheral artery disease.

Who is explicitly excluded. People with type 2 diabetes, obstructive sleep apnea, or metabolic dysfunction–associated steatohepatitis (MASH, previously called NASH) are excluded from the Bridge. A KFF analysis estimated that roughly 3.8 million Medicare beneficiaries met the eligibility criteria in 2023.

How the Bridge interacts with Part D. The Bridge operates outside the Part D benefit — payments do not count toward your Part D true-out-of-pocket total, and the Low-Income Subsidy (Extra Help) does not apply. If you already qualify for a Part D–covered GLP-1 under the type 2 diabetes or cardiovascular indication pathway, that coverage continues under Part D as before.

The Bridge is a demonstration, not a permanent program. CMS designed it as a stopgap while broader coverage reform stalls. If a caregiver is helping a Medicare beneficiary evaluate options, the Bridge is worth checking against the beneficiary’s condition list — but do not assume the door is open indefinitely.

Medicare Advantage plans and Mounjaro: check the formulary before enrollment

Medicare Advantage plans that include Part D coverage follow the same statutory framework — Mounjaro is covered for type 2 diabetes with plan-specific PA and step therapy, and the weight-loss exclusion applies the same way. The variability sits in how each plan sets its formulary, its PA rules, and its step-therapy sequence.

The important consequence: two Medicare Advantage plans available in the same ZIP code can put Mounjaro on different tiers, use different step-therapy chains, and require different documentation. Before enrolling — or before switching between plans — check the specific plan’s formulary against the exact prescription you or your loved one holds.

Two annual windows exist for changing course:

• Annual Enrollment Period (October 15 through December 7): general switching window for all Medicare beneficiaries.
• Medicare Advantage Open Enrollment Period (January 1 through March 31): allows a switch from one Medicare Advantage plan to another, or from Medicare Advantage back to Original Medicare, once per year.

A handful of Special Enrollment Periods can also open the door outside those windows — for example, moving out of a plan’s service area or losing employer coverage.

What to do if your Mounjaro prior authorization is denied

A denial is not a final answer. Federal law gives every Medicare beneficiary a five-level appeals path, and denials that look procedurally routine often reverse on appeal when the medical necessity documentation is presented cleanly.

Level 1 — Redetermination by your plan. Timelines under CY 2026 rule CMS-4208-F: 72 hours expedited, seven days standard for non-drug determinations; Part D-specific timelines apply for the pharmacy pathway. Your prescriber’s office submits the redetermination request with additional documentation.

Level 2 — Independent Review Entity. If the plan upholds its denial, the case moves to a federal contractor that reviews independent of the plan.

Level 3 — Administrative Law Judge hearing. For cases where the disputed amount meets the annual threshold, an ALJ hearing follows.

Level 4 — Medicare Appeals Council review. The Council can affirm, reverse, or remand.

Level 5 — Federal district court. Rarely used, but the option exists for high-value or precedent-setting cases.

Two pieces of context matter for the caregiver reader. First, the same JAMA study cited earlier documents that PA requirements on Part D GLP-1s tightened sharply through 2023–2024 — meaning denials are more common now than they were two years ago. Second, an HHS Office of Inspector General report issued June 2026 examined denial patterns at the three largest Medicare Advantage organizations and found that 36% of long-term acute care denials and 43% of inpatient rehabilitation denials were overturned on appeal (ranging from 14% to 86% by organization). The pattern signals that a well-prepared appeal is worth filing when the medical necessity case is real.

Assistance programs when Medicare doesn’t cover Mounjaro

If Part D denies the prescription and appeals do not reverse the decision, several assistance paths remain — with an important restriction.

Extra Help (Low-Income Subsidy). In 2026, the income limits are $23,940 for an individual and $32,460 for a couple, with resource limits of $18,090 and $36,100 respectively. Beneficiaries who qualify for full Extra Help pay $0 premiums and deductibles under Part D, with copays of about $5.10 for generics and $12.65 for brand-name drugs — and no cost-sharing at all after the annual $2,100 total is reached.

State Pharmaceutical Assistance Programs. Roughly two dozen states operate SPAPs that help pay for prescriptions. Eligibility and covered drugs vary by state.

Manufacturer patient assistance programs. Eli Lilly, Novo Nordisk, and other manufacturers operate patient-assistance programs for people who lack coverage.

The one restriction that catches caregivers off guard. The Mounjaro Savings Card is not available to Medicare beneficiaries. Federal anti-kickback rules prohibit manufacturers from offering copay-assistance cards to people whose prescriptions are paid by federal health programs, including Medicare. A pharmacist who runs a Medicare beneficiary’s Mounjaro through the Savings Card is out of compliance. If a caregiver has been told the Savings Card will lower the price, that guidance is wrong for anyone on Medicare.

When to work with a patient advocate

Deciphering Mounjaro coverage under Medicare in 2026 means holding four moving parts at once: the FDA-approved indication on the prescription, the plan’s formulary and PA rules, the Bridge eligibility criteria, and the assistance-program restrictions. Each piece is knowable; putting them together under time pressure while managing a chronic condition is where the caregiver work compounds.

A patient advocate gathers medical necessity documentation to support the prior authorization, walks the step-therapy sequence through with the prescriber, files the appeal if the first-round denial comes back, and evaluates Medicare Advantage formularies against your prescription list at Annual Enrollment.

Type 2 diabetes is one of the chronic conditions that qualifies for CMS care navigation — a Medicare-billable care coordination benefit. For eligible care navigation services, the ordering provider can bill Medicare for advocate-supported care planning tied to your primary diabetes management. Baba’s patient advocates work under the ordering provider’s supervision — this coordination wraps around your Mounjaro coverage navigation as a covered benefit rather than a separate out-of-pocket cost.

For a companion decision — whether Medicare Advantage or Original Medicare is the better structural fit for your prescription pattern in the first place — see our Medicare Advantage vs Original Medicare guide. If your Mounjaro prior authorization has already been denied and you need the mechanics of the appeal itself, see our how-to guide on appealing a Medicare prior authorization denial.

Frequently asked questions

What’s the difference between Mounjaro and Zepbound?

Same active ingredient — tirzepatide — under two brand names. Mounjaro is FDA-approved for type 2 diabetes and is covered under Medicare Part D. Zepbound is FDA-approved for chronic weight management (and now for obstructive sleep apnea in adults with obesity). Zepbound is not covered under standard Part D for weight loss alone; it is one of the three drugs on the 2026 Medicare GLP-1 Bridge for eligible beneficiaries.

How much does Mounjaro cost with Medicare?

Under Part D with the type 2 diabetes indication, out-of-pocket cost varies by plan tier, coverage phase, and any Extra Help eligibility — the Penn LDI analysis found an average monthly out-of-pocket cost of $196 under Medicare in 2025, up from $99 in 2024. Your specific plan’s Evidence of Coverage will tell you the tier and expected copay for your situation.

Can Medicare Advantage plans cover Mounjaro for weight loss?

Not under the standard Part D benefit — the statutory exclusion under Social Security Act §1860D-2(e)(2) applies to Medicare Advantage prescription drug plans the same way it applies to stand-alone Part D. A small number of Medicare Advantage plans offer supplemental weight-management benefits that could touch adjacent services, but the drug itself for weight loss alone is excluded.

How long does prior authorization take for Mounjaro under Medicare?

Under CY 2026 rule CMS-4208-F, Medicare Advantage non-drug PA decisions must come back within 72 hours expedited or seven days standard. Part D-specific pharmacy PA timelines apply for the drug pathway. If your plan does not decide within the required window, the request is deemed approved.

Can I use the Mounjaro Savings Card with Medicare?

No. Federal anti-kickback rules prohibit manufacturers from offering copay-assistance cards to beneficiaries of federal health programs, including Medicare. If you are on Medicare, the Savings Card is not an option — Extra Help, State Pharmaceutical Assistance Programs, and manufacturer patient-assistance programs are the alternate paths.

What is the Medicare GLP-1 Bridge program?

An 18-month CMS demonstration running July 1, 2026 through December 31, 2027 that provides $50-per-month access to Wegovy, Zepbound KwikPen, and Foundayo for eligible Medicare beneficiaries with obesity plus specific cardiovascular or metabolic conditions. The Bridge excludes people with type 2 diabetes, sleep apnea, or MASH. It operates outside Part D and payments do not count toward your Part D out-of-pocket total.

This information is for educational purposes and should not substitute for professional guidance. Healthcare coverage details vary by individual plan. Consult with Baba’s support team or your insurance provider for information specific to your situation.